Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, CFO

President and CEO

EVP, Global Head RA & Quality

EVP, Chief Sci. & Tech Officer

EVP, Chief Legal Officer

SVP, CFO

EVP, Chief Medical Officer

EVP, Chief Technical Officer

EVP, Head of R&D

SVP, GC & Secretary

Chief Financial Officer

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-31	Premium	acquired	Premium	Premium	Premium	-
2024-03-31	Premium	acquired	Premium	Premium	Premium	-
2024-03-31	Premium	acquired	Premium	Premium	Premium	-
2024-03-31	Premium	acquired	Premium	Premium	Premium	-
2024-03-31	Premium	acquired	Premium	Premium	Premium	-
2024-03-04	Premium	sold	Premium	Premium	Premium	EVP, CFO
2024-03-04	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-04	Premium	sold	Premium	Premium	Premium	EVP, Global Head RA & Quality
2024-03-04	Premium	sold	Premium	Premium	Premium	EVP, Chief Sci. & Tech Officer
2024-03-04	Premium	sold	Premium	Premium	Premium	EVP, Chief Legal Officer
2024-01-08	Premium	acquired	Premium	Premium	Premium	EVP, Chief Sci. & Tech Officer
2024-01-08	Premium	acquired	Premium	Premium	Premium	EVP, CFO
2024-01-08	Premium	acquired	Premium	Premium	Premium	EVP, Global Head RA & Quality
2024-01-08	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-01-08	Premium	acquired	Premium	Premium	Premium	EVP, Chief Legal Officer
2023-11-16	Premium	sold	Premium	Premium	Premium	EVP, Global Head RA & Quality
2023-11-16	Premium	sold	Premium	Premium	Premium	EVP, Chief Sci. & Tech Officer
2023-11-16	Premium	sold	Premium	Premium	Premium	EVP, Chief Legal Officer
2023-11-16	Premium	sold	Premium	Premium	Premium	President and CEO
2023-11-16	Premium	sold	Premium	Premium	Premium	SVP, CFO
2023-11-16	Premium	sold	Premium	Premium	Premium	EVP, Chief Medical Officer
2023-11-14	Premium	bought	Premium	Premium	Premium	-
2023-11-13	Premium	bought	Premium	Premium	Premium	-
2023-11-10	Premium	bought	Premium	Premium	Premium	-
2023-11-10	Premium	bought	Premium	Premium	Premium	-

ATRA - Atara Biotherapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for ATRA